Skip to Navigation
Skip to Main Content
Skip to Related Content
to view your mail
Yahoo Finance Plus
U.S. markets closed
SPDR Bloomberg Barclays 1-3 Month T-Bill ETF (BIL)
NYSEArca - NYSEArca Delayed Price. Currency in USD
Add to watchlist
At close: 4:00PM EDT
24 reactions on $BIL conversation
Sign in to post a message.
If you are new to mine:
- MINE is a speculation stock.
- New leaders took over last year and pivoted company mission
- Places like
Schwab sti misstate this company’s sector and description base on old leader and documents.
- Minerco is in infantile stages of an infantile market.
- We are waiting for product and revenue coming SOON.
- ACCUMULATE this if you have foresight into the MANY $bil sectors psilocybin will disrupt, and consider Jamaica has NO REGULATIONS limiting export of this burgeoning LEGAL market.
- International fiat controlled substance regulation issue already accounted for with a digital token currency.
Year of the ox brings the bull market. Invest heavily and wisely and you shall be rewarded.
BIL - Why the drop yesterday - Jay
Warren Buffet has invest $bil in SU. This company is so under Value, it's not even funny.
Take it from me, don't be a peon with those dumping 35 mil shares today, as now is the time to be buying. Right where peon would be selling now, is the time to be buying. 6 bucks is like a 40% gap ... that's HUGE!!! If you can risk going all the way, as this October swoon I felt was coming long ago (confirmed by hefty rise in shorting), and wait for the final word is the only way. Will look as ugly as possible, and boom it's back. Something about the month (fiscal year ends/tax selling, etc. - which also justifies the higher volume), the options, the shorts, whatever peon never knows, other then trial is still on for December, so who cares about that price in October? The merger is 1 Judge's ruling away, simple as that, and the real cash cow will moo.
But hey, this is brutal. If no other company had an unjust lifeline account, while Sprint had like a million of them, someone has to pay (claure/combes/gracia/davies). Down to 6 bucks a share now all thanks to those dirty execs. while shorts soared and price tanked, it to me isn't real. What it really is, what it always really is, is an illusion. Things are not (never) as they seem, and they tend to either seem to be too good, or too bad. And, tends to be the opposite of what the peon brain is thinking, which is sprint is looking bad and sell. So sorry, TM confirmed is still booming and merging, with bullish thoughts, December trial date now only like 1 month away, and appears to be the easiest slam dunk case. No couple of $bil here or $bil there after all achieved to date, cannot be amicably resolved by these guys who have the most at stake. Buy/Hold S with TMUS over $80 & S under $6.50. $81.5 to $6.1 right now, is a buy peon ... buy these shares now peon, so that you may 1 day next year escape peonville.
Ken is new at this, and ALSO seems to share Tom's odd perspective that a blockbuster drug still showing 16% YoY increase in prescription numbers SIX YEARS post-introduction is failing.
Incyte's stock price is down because of some actual problems the company has had, and also because of a vicious bearish public relations campaign. None of which is going to do his beloved imetelstat a bit of good.
The present market valuation of Incyte concedes that Jakafi sales will eventually top $2.4 bln, with comparable Jakavi sales, and also that Olumiant sales will hit $1bln. But it anticipates far-below-average returns from Incyte's R&D program Assume industry average returns on R&D investment and you get back above the old high on an investment time scale. Assume that Lilly can defend the international label for Olumiant, and get modest improvement of the US label, and that $bil looks awfully conservative.
Two near-ish term events have a lot of potential. There aren't THAT many dollars at stake in capmatinib approval, but having developed a lung cancer drug could boost the company's [Wall] street cred substantially. And again, while the market is kind of niche (actually, not a whole lot smaller than higher-risk MF), getting high tolerability lasting 2 years or more out of the delta drug would generate both street cred and lots of usage opportunities.
I will not rest till this stock is under a 1 $bil market cap.
1 $bil sales 2019
Good earnings over 650 $mil cash
HCC approved EU
$40 mil payment from Ipsen
HCC liver FDA 1/19
It’s a Steal
One - 3 month treasury yields down to < .05%. BIL's div will dry up by April or May. Stock will be OK, but yield will be almost zip...........Kel.........a holder
just in, trump will levy another 267 $bil tariffs on china. thats a shocker just before the g20 friday.
desperate move by maxim...not much growth for the last 10yrs...acquired mediocre low quality companies...has over $bil in debt...
the current inexperienced CEO destroyed it...
Don't you all wish you had your money here right now.
So, no more dividends now? may be better off with a FDIC insured savings account at a bank.
Shorts need your shares! Any partnership or sale of just one of their potentially multi $bil drugs and Arena becomes a $100+ stock! Hold and buy when you can
why the big drop on Wednesday morning (Dec.19)?
Does anyone know why the yield ion his ETF
s much lower than the 1 month & 3 month T-Bill yields?
F is flat today and GM down almost 1%. No sense in that. Good time for those 37 mil shares short to start covering. Next wks earnings could put a massive hurt on shorts. Last Q GM beat by .34 and about a $bil.
Yahoo Finance Insights
BIL reached a 52 Week high at 94.18
Yahoo Finance Insights
BIL reached a 52 Week high at 94.18
New COVID stimulus checks are coming to some US workers
Design simplicity and celebrity collaborations fuel Crocs Q3 sales growth: CEO
Yahoo Finance Video
Pain at the pump: California gas prices are sky high, with one town charging almost $8 a gallon
Advertise with us
© 2021 Verizon Media
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research